In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...